Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Has No Competitors

Frequently posters tell of companies that Anavex must compete with; that other, bigger pharmaceuticals can out-compete little Anavex.

One competes with competitors playing the same game, with the same ball, by the same rules, etc.

Anavex has no competitors. No one else has a central nervous system drug with a) the same or similar mechanism of action of Anavex 2-73, b) any equivalent Phase 1 and 2 human clinical trial outcomes for Alzheimer’s, particularly profound safety and long-term efficacy, c) applications for a wide diversity of CNS diseases and conditions, d) providing control of epileptic episodes, and finally, e) has the strong potential to safely induce healthful sleep.

No competition. FDA does not approve new drugs because they would compete with existing ones. Presently, there are but four Alzheimer’s drugs; the most prevalent is Aricept. To get approved, Anavex 2-73 needs merely to eclipse the very meager efficacies of that drug. A very low bar, indeed.